Mohammad Salameh M.D. 

Director of adult Medical Oncology and 

Bone Marrow Transplantation

Business Tel: 06-4638240
Home Tel: 06- 5348377
Mobile : 079- 5510898
Fax: 06-4638246




Mohammad Salameh M.D.       
Jan. 2nd 1955    Date of birth

Married with three children    
Name of spouse : Liana
Director of adult Medical Oncology and Bone Marrow Transplantation at Al-Amal
Cancer Center
Amman –Jordan
9/99-up to date.    


1) Bone Marrow Transplantation Fellowship
University of Texas Medical Branch at Galveston

July 1997-June 1999
Doing both autologous and allogenic, Peripheral Stem cell transplantation and Bone marrow transplantation, for different malignancies as Acute and Chronic Leukemias, Lymphoma both Hodgkin’s and Non Hodgkin’s Lymphoma, Breast
Cancer Sarcoma, Multiple Mycloma; Lung Cancer and Neuroblastoma.

Actively involved in writing different active protocols for BMT.

Teaching Medical Oncology fellows who rotates at BMT unit as well as medical residents and physician assistants.
2) Medical Oncology Fellowship.
UTMB – Galveston TX – USA

Seeing all patients who need oncology evaluation and with initiation of the investigation and treatment under the care of medical oncologist.

Rotating in the medical oncology wards, dealing with all the acute medical emergencies.

Actively involved in basic as well as clinical researches in medical oncology.
3) Internal Medicine Residency Program
Seton Hall University, Newark – NJ, USA

Rotating in three different hospitals in Newark, Elizabeth and Paterson – NJ with excellent evaluation around all physicians.

Awarded Dr. Philip Di-Ambola memorial resident award for excellent in Teaching 1995.

Excempted by one year from my training which was approved by American Board of Int. Medicine.
4) Int. Medicine residency Jordan University Hospital, Amman – Jordan 1/7/1982-30/6/1985
5) Rotating Internship Jordan University Hospital, Amman – Jordan 1/7/1981-30/6/1982


1) University of Texas Medical Branch at Galveston, TX, USA - BMT fellowship -1999.

2) American Board of Medical Oncology - 1997.

3) University of Texas Medical Branch at Galveston, TX, USA - Medical Oncology Fellowship - 1997.

4) American Board of Int. Medicine -1995.

5) Int. Medicine residency program, Seton Hall University, Newark, NJ, USA -1995.

6) Arab –Board of Int. Medicine (II) written part -1990.

7) Jordanian Board of Int. Medicine -1988.

8) Master degree – Int. Medicine, Jordan University -1985.

9) MBBS- Jordan University -1981.


1)Director of Adult Medical Oncology at    Al-Amal Cancer Center   9/1999-up date.

2) Intersit Security Forces Hospital Riyadh – Saudi Arabia 1985-1993.


1) Dr Philip R- Di- Ambola Memorial Resident Award for excellent in teaching, Saint
Michael’s Medical Center, NJ, USA 1995.


1) John T, Piper, Sharad Singhal, Mohammad Salameh, Robart Torman, Yogesh
Awasti, Sanjay Awast, Mechanisms of Anti Carcinogenic Properties of Curcumin, The effect of glutathione linked detoxification enzymes in rat liner.

The International Journal of Biochemistry and Cell Biology. 30 (1998) 445-456.

2) Activation of the RAS/RAF-1 MEK Signaling Pathway Inhibit Taxel and Vincristine
– Mediated Apoptosis in human TF-1 mycliod leukemia cells.
M. Carrol, Y. GU and M. Salameh ASH Abstract 1997.

Clinical Trials:

Principle investigator and Co- investigator.

1) A piolet study of related- Doner Allogenic Peripheral blood stem cell
Transplantation for the treatment of patient with advanced hematological malignancy.
2) A phase I study of Escalating dose of topotecan with Carbo platin – VP16 in
treatment of patient with different malignancies using peripheral blood stem cell
transplantation rescue.
3) A phase II trials of high dose Busulfan and Cyclophosphamide followed by
peripheral blood stem cell rescue for patient with intermediate or high grade NHL or
Hodgkin’s disease in sensitive relapse.
4) A phase II trial of high dose BUCY followed by P.B.SC.T for patient with locally
advanced breast cancer or metastatic disease.
5) A phase II study of using neoadjuvant chemotherapy using Docetaxel and
Carboplatin for patient with locally advanced breast cancer.
6) A phase II study of using Doxil for treatment of refractory metastatic breast cancer.
7) A phase II study of using Bryostatin with or without Cytoxan, VP16 and Vincristine
for patient with AIDs related Non-Hodgkin’s lymphoma.


1) American Society of Clinical Oncology (ASCO).
2) American Society of Hematology (ASH).
3) American Collage of Physician (ACP).



























HOME| Contact

Copyrights 1995-2007 Created and maintained by MBC